Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PCL, PWRM, LXK, DRC - Market Report From DrStockPick.com!

drstock-2-3

signup3m


power3

Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

**************************************************************

Dresser-Rand Group Inc. (NYSE:DRC) announced on Wednesday November 10, 2010 that the Company will present at Citi’s 7th Annual Small & Mid Cap Conference on Wednesday, November 17, 2010. Mark Baldwin, Executive Vice President and Chief Financial Officer, will participate in the conference at the Four Seasons Hotel Las Vegas, 3960 Las Vegas Boulevard South, Las Vegas, Nevada, 89119.

Dresser-Rand Group Inc. is the global supplier of custom-engineered rotating equipment solutions for the applications in the oil, gas, petrochemical and industrial process industries.

**************************************************************

Lexmark International, Inc. (NYSE:LXK) announced on Friday November 5, 2010 the company is combining its two printing organizations, the Printing Solutions and Services Division (PS&SD) and the Imaging Solutions Division (NYSE:ISD), into a single organization named Imaging Solutions and Services (NYSE:ISS). As Lexmark continues to shift its inkjet technology upstream, the combination of the two divisions into ISS enables Lexmark to more easily execute its strategy of targeting and capturing higher usage segments of the output marketplace, from small offices to global enterprises looking for managed print services. This move will also allow the company to further unify its sales, marketing, and research and development (R&D) of new products and services.

Lexmark International, Inc., is engaged in developing, manufacturing and supplying printing and imaging solutions for offices and homes. Lexmark’s products include laser printers, inkjet printers, multifunction devices.

**************************************************************

Plum Creek Timber Co. Inc. (NYSE:PCL) announced on Monday November 8, 2010 the pricing of its public offering of $575 million aggregate principal amount of senior unsecured notes due 2021. The notes will bear interest at 4.70% per year and mature on March 15, 2021. The offering is expected to close on November 15, 2010. Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated and RBS Securities Inc. acted as joint book-running managers of the offering.

Plum Creek Timber Company, Inc. (Plum Creek) is a private timberland owner in the United States. As of December 31, 2009, Plum Creek owned 7 million acres of timberlands located in 19 states.

*******************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).